Ghrelin treatment in heart failure patients showed increased contractility of the heart
Stockholm, Sweden, March 14 , 2023 AnaCardio´s founder Prof Lars Lund and colleagues from The Karolinska Institutet publish study on ghrelin treatment in patients with heart failure and in isolated heart cells, demonstrating increased contractility and a novel mechanism of action AnaCardio, a Swedish clinical-stage biopharmaceutical company focused on developing novel contractile agents with a […]
AnaCardio Receives Regulatory Approval to Start a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK
Stockholm, Sweden, November 17, 2022 AnaCardio today announces approval for the GOAL-HF1 Phase 1b/2a study from the competent authorities and ethics committes in Sweden, The Netherlands, Italy and the United Kingdom. This 28-day study will evaluate the effects of orally administered AC01 on safety, tolerability, pharmacokinetics and a series of pharmacodynamic readouts in patients with […]